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2012.11.0Abstract Intensity-modulated radiotherapy is used for delivering more efﬁcient homogenous dose
to the target and lowering of dose to the surrounding normal tissues. However, a second malignant
neoplasm may develop after prolonged latent period. The use of modern precise radiotherapy tech-
niques in the pediatric age group has many controversial issues in spite of its proven dosimetric dis-
tribution advantages and the considerable decrease of normal tissue complication probability
(NTCP). This concern is due to many factors; mainly the exposure of a larger volume of normal
tissues to low dose radiotherapy. Children have more proliferating tissues compared to the adults.
However, the epidemiological data did not detect an increase in the incidence of radiation-induced
second malignancy. This issue is still controversial as IMRT and other precise radiotherapy
techniques were not widely used except recently. This may entail a thorough careful follow up
for children treated with these techniques to detect any incidence increase.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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motherapy and autologous stem cell transplant in the treat-
ment of high risk neuroblastoma (NB) had led to excellentment, Children’s Cancer Hos-
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02local control rates exceeding 80% [1]. Abdominal NB is often
located in the midline and paraspinal region encroaching on
one or both kidneys. The recommended radiation dose is in
the range of 21–36 Gy depending on the presence of residual
tumors post surgical excision. With the conventional 3 dimen-
sional conformal radiotherapy (3DCRT) the dose received by
the kidney(s) may exceed its tolerance. Adding to this, the sit-
uation in NB is more complicated by the administration of
nephrotoxic chemotherapy mainly cisplatin. For more efﬁcient
homogenous dose to the target and lowering of dose to the
kidneys, Nazmy and Khafaga [2] used the intensity modulated
radiotherapy (IMRT) in 13 NB children after autologous stem
cell transplant. Their results showed good survival rates with-
out late complications (skeletal asymmetry or second malig-
nancy) at a median of 26 months post IMRT. Although thisand hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
2 M.S. Zaghloulinterval is short for the detection of survival advantage and to
rule out such complications, yet they could illustrate a clear
dosimetric advantage of IMRT in the kidneys, liver and
vertebrae compared to 3DCRT. Hillbrand et al. [3] showed
earlier in a dosimetric study that volumes of the kidneys and
liver irradiated at the level of the tolerance dose were decreased
by 65% and 75% respectively for abdominal NB patients
treated with IMRT.
The use of modern precise radiotherapy techniques includ-
ing IMRT, volumetric modulated arc radiotherapy (VMAT),
helical tomotherapy (HT) and extracranial stereotactic radio-
therapy in the pediatric age group has many controversial is-
sues in spite of its proven dosimetric distribution advantages.
The more homogenous dose to the target volume with much
lesser dose to the surrounding organs at risk (OAR) deﬁnitely
leads to a considerable decrease of normal tissue complication
probability (NTCP). The potential of development of radia-
tion-induced second malignant neoplasm (SMN) is a major
concern in such group of patients. This concern is due to many
factors. The most important one is the exposure of a larger
volume of normal tissues to low dose (peripheral dose) radio-
therapy. Children are a major concern as they have more pro-
liferating tissues with more numbers of stem cells compared to
the adults. Furthermore, promotion of growth hormones to
tissue is likely to be greater during young age [4]. Hall and
Wuu [5] hypothesized the increase of SMN in patients 10 years
after IMRT by 0.75% (from 1% after conventional to 1.75%
after IMRT) depending upon a hypothetical mathematical
model. More monitor units are used to deliver IMRT than
3DCRT to deliver the same dose which may translate into
more radiation leakage to different organs at risk and to the
entire patient body. It is well known that the delay between
irradiation and emergence of SMN is seldom be less than
10 years. This delay may cause a considerable under- or
over-estimation, unless actuarial cumulative incidence is com-
puted [4]. Moderate or high doses of radiation with the result-
ing cell kill effect disorganize the tissues and lower the efﬁcacy
of proliferation control of the mutated cells to develop mani-
fest cancer [6].
Epidemiological data did not detect cancer excess in chil-
dren where a dose below 100 mGy is delivered at a high dose
rate or 200 mGy delivered at a low dose rate [7]. The extrapo-
lation of the mathematical models to real patients is still of
dubious validity and needs conﬁrmatory revision. The fear ex-
pressed by some radiobiological researchers [8–10] that precise
radiotherapy including IMRT, HT, VART may increase the
incidence of SMN through increasing the volume of normal
tissues receiving low dose is a subject for extensive debate
and controversy. This low dose is primarily caused by a leak-
age through the accelerator head, jaws and multileaf collima-
tor (MLC) together with the internal scatter within the
patient. Secondary radiation from MLCs contributes a signif-
icant portion of low dose in IMRT plans [11]. Athar and Paga-
netti [12] estimated that children and young patients showed
signiﬁcantly higher risk than adults and deep seated tumors
are associated with an elevated risk of radiation-induced
SMN than shallow treatment ﬁelds. They estimated further
the uncertainty in their suggested model to be in the range of
50%. This risk is usually related to the integral dose or low
dose volume. The integral dose equals to the mean dose mul-
tiplied by the volume of each structure. The low dose volume
is deﬁned as the volume receiving a total dose of 2 Gy or more.Tubiana [4] in his review showed that second primary malig-
nancies are observed for in-ﬁeld organs receiving doses in ex-
cess of 2 Gy. The IMRT had higher integral dose than
3DCRT in some studies [13,14] and others reported a decrease
[15,16], while some others reported mixed results for different
sites when comparing the non-tumor integral dose with IMRT
and HT [17]. Yang et al. [18] reported that in spite of the in-
crease of the volume of normal tissues receiving low dose
yet, the integral doses to the normal tissues did not increase
with IMRT or HT compared to 3DCRT. In the contrary, they
discovered that the integral doses of the normal tissues and the
whole body were signiﬁcantly lower with IMRT. Speciﬁcally,
Aoyama et al. [15] reported that IMRT and HT resulted in
5% and 4% lower integral dose to normal tissue, respectively.
On the contrary, Lian et al. [13] reported a signiﬁcant increase
in the integral dose of normal tissues with IMRT and HT com-
pared to 3DCRT. This discrepancy in the 2 studies was prob-
ably due to the larger volume ratio of the normal tissues to
PTV in Lian et al. study. The volume of peripheral dose or
low dose depends on the technical equipments, technology
and on the inverse planning and segmentation algorithms used.
Therefore, the peripheral dose may vary in the pre IMRT era
than in recent days [19]. Salz et al. [19] measured the peripheral
dose for a 4-year old child irradiated for brain tumor using
IMRT and 3DCRT. The measurements showed an increase
of the peripheral dose in IMRT measuring 9 mGy; a dose sim-
ilar to the dose of CT scan or the dose of a veriﬁcation ﬁlm
shot with a monitor unit.
In conclusion, IMRT has to be used in children whenever
necessary and when it is needed together with activating the ex-
tended and prolonged follow up programs in order to detect
any actual increase in the SMN and correlate it to the possible
hazard factors. On the other hand, the usage of treatment
plans and algorithms with less monitor units should be encour-
aged to avoid part of the dose outside the targets. Further-
more, changes in the hardware of the machines (linear
accelerators, HT, Cyberknife) can reduce the peripheral dose.
It was reported that ﬂattening ﬁlter-free beams in IMRT re-
duce the head scatter dose down to 52% in 6 MV and 65%
in 10 MV photons [20].Conﬂict of interest
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